(NASDAQ: VERA) Vera Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.4%.
Vera Therapeutics's earnings in 2025 is -$251,943,000.On average, 15 Wall Street analysts forecast VERA's earnings for 2025 to be -$299,950,486, with the lowest VERA earnings forecast at -$330,789,385, and the highest VERA earnings forecast at -$294,005,176. On average, 14 Wall Street analysts forecast VERA's earnings for 2026 to be -$311,393,609, with the lowest VERA earnings forecast at -$402,209,820, and the highest VERA earnings forecast at -$213,455,812.
In 2027, VERA is forecast to generate -$205,253,842 in earnings, with the lowest earnings forecast at -$326,403,919 and the highest earnings forecast at $56,384,554.